Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT04477863
Recruiting Observational

Follow-up With Preimplantation Genetic Testing Patients

NCT04477863 · tracked via the Priya Life Science USA tracker
Sponsor
Genomic Prediction Inc
Phase
Observational
Started
2020-07-11
Last updated
2025-08-26

Condition(s) studied

InfertilityGenetic DiseaseIVF

Investigational drug(s) / intervention(s)

Follow-up Interview

Follow-up Interview: Non Applicable

Study summary

The main purpose of this study is to perform longitudinal evaluations of clinical outcomes and personal perspectives following utilization of preimplantation genetic testing (PGT). Patients indicating willingness to participate in research during informed consent to perform PGT will be eligible for inclusion. A licensed genetic counselor will conduct a recorded interview.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients indicating willingness to participate in research during informed consent to perform PGT Exclusion Criteria: * Patients who opted out of participating in research during informed consent to perform PGT

Primary outcome measure(s)

  • Patient perspectives on PGT — 2 years
    Analysis of interview responses

Trial sites (1)

FacilityCityRegionStatus
Genomic Prediction Clinical Laboratory North Brunswick New Jersey Recruiting

More Genomic Prediction Inc. trials in the USA

ANXA5 M2 Haplotyping in IVF Patients and Embryos Active, not recruiting
Cell Free Preimplantation Genetic Testing Starting soon
Preimplantation Genetic Testing in Women of Advanced Maternal Age Recruiting
GEnetic Testing in Elective Single Embryo Transfer (GETSET): A Randomized Clinical Trial Recruiting

Other trials for the same condition

To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That Develop to the Point That They Are Able to be Transferred) in IVF Cycles. Active, not recruiting
Aspire In Vitro Maturation Study Enrolling by invitation
Opt-IVF for Personalized Medicine for Normal Responders Active, not recruiting
ANXA5 M2 Haplotyping in IVF Patients and Embryos Active, not recruiting
Non-Euploid Embryo Transfer (NEET) Registry Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04477863 on ClinicalTrials.gov ↗ ← All trials in the USA